LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: International guidelines regarding the role of IVIG in the management of Rh- and ABO-mediated haemolytic disease of the newborn.

Lieberman, Lani / Lopriore, Enrico / Baker, Jillian M / Bercovitz, Rachel S / Christensen, Robert D / Crighton, Gemma / Delaney, Meghan / Goel, Ruchika / Hendrickson, Jeanne E / Keir, Amy / Landry, Denise / La Rocca, Ursula / Lemyre, Brigitte / Maier, Rolf F / Muniz-Diaz, Eduardo / Nahirniak, Susan / New, Helen V / Pavenski, Katerina / Dos Santos, Maria Cristina Pessoa /
Ramsey, Glenn / Shehata, Nadine

British journal of haematology

2022  Volume 198, Issue 1, Page(s) 183–195

Abstract: Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks. ... ...

Abstract Haemolytic disease of the newborn (HDN) can be associated with significant morbidity. Prompt treatment with intensive phototherapy (PT) and exchange transfusions (ETs) can dramatically improve outcomes. ET is invasive and associated with risks. Intravenous immunoglobulin (IVIG) may be an alternative therapy to prevent use of ET. An international panel of experts was convened to develop evidence-based recommendations regarding the effectiveness and safety of IVIG to reduce the need for ETs, improve neurocognitive outcomes, reduce bilirubin level, reduce the frequency of red blood cell (RBC) transfusions and severity of anaemia, and/or reduce duration of hospitalization for neonates with Rh or ABO-mediated HDN. We used a systematic approach to search and review the literature and then develop recommendations from published data. These recommendations conclude that IVIG should not be routinely used to treat Rh or ABO antibody-mediated HDN. In situations where hyperbilirubinaemia is severe (and ET is imminent), or when ET is not readily available, the role of IVIG is unclear. High-quality studies are urgently needed to assess the optimal use of IVIG in patients with HDN.
MeSH term(s) Blood Group Incompatibility ; Erythroblastosis, Fetal/drug therapy ; Exchange Transfusion, Whole Blood ; Female ; Humans ; Immunoglobulins, Intravenous/therapeutic use ; Infant, Newborn ; Phototherapy
Chemical Substances Immunoglobulins, Intravenous
Language English
Publishing date 2022-04-12
Publishing country England
Document type Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID 80077-6
ISSN 1365-2141 ; 0007-1048
ISSN (online) 1365-2141
ISSN 0007-1048
DOI 10.1111/bjh.18170
Shelf mark
Uh III Zs.182: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top